Inappropriate gene activity disrupts chromosome segregation and generates a chromosomal abnormality, known as uniparental disomy, present in many cancer cells.
Each year, CCR licenses new technologies, publishes articles in peer-reviewed journals, opens new clinical trials and brings in thousands of patients and trainees.